Literature DB >> 15962085

Angiogenesis as an indicator of metastatic potential in papillary thyroid carcinoma.

Elaine Stabenow1, Marcos Roberto Tavares, Alexandre Muxfeldt Ab'Saber, Edwin Roger Parra-Cuentas, Leandro Luongo de Matos, Esmeralda Miristene Eher, Vera Luiza Capelozzi, Alberto Rosseti Ferraz.   

Abstract

UNLABELLED: Angiogenesis is new blood vessel formation, a process that can lead to tumor development. Microvessel count has been correlated to metastasis in some neoplasias.
PURPOSE: To determine if measurement of microvessel density is useful in predicting metastasis to the cervical lymph node and prognosis in patients with papillary thyroid carcinoma.
METHODS: A retrospective analysis was performed in 30 patients that had undergone total thyroidectomy. They were divided in 2 groups of 15 patients--with and without metastatic disease. Immunohistochemistry was used to detect expression of CD34 in archival paraffin-embedded papillary thyroid tumors, and microvessel density was calculated based on it. Association between microvessel density and the presence of metastasis, according to histological subtype, disease recurrence, and AMES prognostic index groups was determined through statistical analysis.
RESULTS: The median microvessel density for the patient group without metastasis (200.0 microvessels/mm2) was apparently, but not significantly, less than that observed among metastatic disease patients (254.4 microvessels/mm2) (P=.20). When papillary carcinoma subtypes were analyzed, this difference became significant (P=02). The follicular variant exhibited a greater microvessel density than the other subtypes, independent of metastasis presence. There was an apparent, but not significant, tendency for a larger median microvessel density in the group of patients that presented recurrence (294.4 microvessels/mm2 vs 249.6 microvessels/mm2, P=.11). There was no relationship between risk level and microvessel density: in the low- and high-risk groups, the median MVD was 304.0 microvessels/mm2 and 229.6 microvessels/mm2, respectively (P=.27).
CONCLUSIONS: The results suggest that angiogenesis is more intense among metastatic tumors in the classic and the tall cell variants, indicating that microvessel count can be an indicator of the potential for metastasis in these subtypes of papillary thyroid carcinoma. Patients that developed recurrent disease had a tendency to exhibit higher angiogenesis; however, there was no association between microvessel density and the AMES prognostic index.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15962085     DOI: 10.1590/s1807-59322005000300009

Source DB:  PubMed          Journal:  Clinics (Sao Paulo)        ISSN: 1807-5932            Impact factor:   2.365


  5 in total

1.  Superb microvascular imaging compared with contrast-enhanced ultrasound to assess microvessels in thyroid nodules.

Authors:  Zhao Yongfeng; Zhou Ping; Peng Hong; Liu Wengang; Zhang Yan
Journal:  J Med Ultrason (2001)       Date:  2020-03-03       Impact factor: 1.314

2.  Immunohistochemistry as an important tool in biomarkers detection and clinical practice.

Authors:  Leandro Luongo de Matos; Damila Cristina Trufelli; Maria Graciela Luongo de Matos; Maria Aparecida da Silva Pinhal
Journal:  Biomark Insights       Date:  2010-02-09

Review 3.  Angiogenesis in Malignant Thyroid Tumors.

Authors:  Matvey Vladimir Sprindzuk
Journal:  World J Oncol       Date:  2011-01-01

4.  Microvessel density in differentiated thyroid carcinoma: A systematic review and meta-analysis.

Authors:  Konstantinos Perivoliotis; Athina A Samara; Prodromos Koutoukoglou; Panagiotis Ntellas; Katerina Dadouli; Sotirios Sotiriou; Maria Ioannou; Konstantinos Tepetes
Journal:  World J Methodol       Date:  2022-09-20

Review 5.  Total Thyroidectomy with Central Node Dissection is a Valuable Option in Papillary Thyroid Cancer Treatment.

Authors:  Marija Pastorčić Grgić; Boris Stubljar; Pavao Perše; Mirta Zekan Vučetić; Sanda Šitić
Journal:  Acta Clin Croat       Date:  2020-06       Impact factor: 0.780

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.